Clinical and hematological relevance of JAK2 V617F and CALR mutations in BCR-ABL-negative ET patients

References

• Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937–951. doi: 10.1182/blood-2009-03-209262
   PubMed Web of Science ®Google Scholar
• Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054–1061. doi: 10.1016/S0140-6736(05)74230-6
   PubMed Web of Science ®Google Scholar
• Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387–397. doi: 10.1016/j.ccr.2005.03.023
   PubMed Web of Science ®Google Scholar
• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–2405. doi: 10.1182/blood-2016-03-643544
   PubMed Web of Science ®Google Scholar
• James C, Ugo V, Le Couédic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144–1148. doi: 10.1038/nature03546
   PubMed Web of Science ®Google Scholar
• Li N, Yao QM, Gale RP, et al. Frequency and allele burden of CALR mutations in Chinese with essential thrombocythemia and primary myelofibrosis without JAK2(V617F) or MPL mutations. Leuk Res. 2015;39:510–514. doi: 10.1016/j.leukres.2015.02.006
   PubMed Web of Science ®Google Scholar
• Lin Y, Lui E, Sun Q, et al. The prevalence of JAK2, MPL, and CALR mutations in Chinese patients with BCR-ABL1-negative myeloproliferative neoplasms. Am J Clin Pathol. 2015;144:165–171. doi: 10.1309/AJCPALP51XDIXDDV
   PubMed Web of Science ®Google Scholar
• Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3:e270. doi: 10.1371/journal.pmed.0030270
   PubMed Web of Science ®Google Scholar
• Pardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006;108:3472–3476. doi: 10.1182/blood-2006-04-018879
   PubMed Web of Science ®Google Scholar
• Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369:2379–2390. doi: 10.1056/NEJMoa1311347
   PubMed Web of Science ®Google Scholar
• Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369:2391–2405. doi: 10.1056/NEJMoa1312542
   PubMed Web of Science ®Google Scholar
• Wang WA, Groenendyk J, Michalak M. Calreticulin signaling in health and disease. Int J Biochem Cell Biol. 2012;44:842–846. doi: 10.1016/j.biocel.2012.02.009
   PubMed Web of Science ®Google Scholar
• Rumi E, Pietra D, Ferretti V, et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood. 2014;123:1544–1551. doi: 10.1182/blood-2013-11-539098
   PubMed Web of Science ®Google Scholar
• Tefferi A, Lasho TL, Finke C, et al. Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact. Leukemia. 2014;28:1568–1570. doi: 10.1038/leu.2014.83
   PubMed Web of Science ®Google Scholar
• Rumi E, Pietra D, Pascutto C, et al. Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. Blood. 2014;124:1062–1069. doi: 10.1182/blood-2014-05-578435
   PubMed Web of Science ®Google Scholar
• Cazzola M, Kralovics R. From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms. Blood. 2014;123:3714–3719. doi: 10.1182/blood-2014-03-530865
   PubMed Web of Science ®Google Scholar
• Rotunno G, Mannarelli C, Guglielmelli P, et al. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood. 2014;123:1552–1555. doi: 10.1182/blood-2013-11-538983
   PubMed Web of Science ®Google Scholar
• Singdong R, Siriboonpiputtana T, Chareonsirisuthigul T, et al. Characterization and prognosis significance of JAK2 (V617F), MPL, and CALR mutations in Philadelphia-negative myeloproliferative neoplasms. Asian Pac J Cancer Prev. 2016;17:4647–4653.
   PubMedGoogle Scholar
• Sultan S, Irfan SM. Acquired JAK-2 V617F Mutational analysis in Pakistani patients with essential thrombocythemia. Asian Pac J Cancer Prev. 2015;16:7327–7330. doi: 10.7314/APJCP.2015.16.16.7327
   PubMedGoogle Scholar
• Rampal R, Al-Shahrour F, Abdel-Wahab O, et al. Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. Blood. 2014;123:e123–e133. doi: 10.1182/blood-2014-02-554634
   PubMed Web of Science ®Google Scholar
• Azzato EM, Bagg A. Molecular genetic evaluation of myeloproliferative neoplasms. Int J Lab Hematol. 2015;37(Suppl 1):61–71. doi: 10.1111/ijlh.12353
   PubMed Web of Science ®Google Scholar
• Park SH, Chi HS, Cho YU, et al. The allele burden of JAK2 V617F can aid in differential diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasm. Blood Res. 2013;48:128–132. doi: 10.5045/br.2013.48.2.128
   PubMedGoogle Scholar
• Cabagnols X, Favale F, Pasquier F, et al. Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients. Blood. 2016;127:333–342. doi: 10.1182/blood-2015-07-661983
   PubMed Web of Science ®Google Scholar
• Milosevic Feenstra JD, Nivarthi H, Gisslinger H, et al. Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms. Blood. 2016;127:325–332. doi: 10.1182/blood-2015-07-661835
   PubMed Web of Science ®Google Scholar
• Kim SY, Im K, Park SN, et al. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable. Am J Clin Pathol. 2015;143:635–644. doi: 10.1309/AJCPUAAC16LIWZMM
   PubMed Web of Science ®Google Scholar
• Gardner JA, Peterson JD, Turner SA, et al. Detection of CALR mutation in clonal and nonclonal hematologic diseases using fragment analysis and next-generation sequencing. Am J Clin Pathol. 2016;146:448–455. doi: 10.1093/ajcp/aqw129
   PubMed Web of Science ®Google Scholar
• Clinton A, McMullin MF. The Calreticulin gene and myeloproliferative neoplasms. J Clin Pathol. 2016;69:841–845. doi: 10.1136/jclinpath-2016-203899
   PubMed Web of Science ®Google Scholar
• Wojtaszewska M, Iwola M, Lewandowski K. Frequency and molecular characteristics of calreticulin gene (CALR) mutations in patients with JAK2 -negative myeloproliferative neoplasms. Acta Haematol. 2015;133:193–198. doi: 10.1159/000366263
   PubMed Web of Science ®Google Scholar
• Nunes DP, Lima LT, Chauffaille Mde L, et al. CALR mutations screening in wild type JAK2(V617F) and MPL(W515 K/L) Brazilian myeloproliferative neoplasm patients. Blood Cells Mol Dis. 2015;55:236–240. doi: 10.1016/j.bcmd.2015.07.005
   PubMed Web of Science ®Google Scholar
• Labastida-Mercado N, Galindo-Becerra S, Garcés-Eisele J, et al. The mutation profile of JAK2, MPL and CALR in Mexican patients with Philadelphia chromosome-negative myeloproliferative neoplasms. Hematol Oncol Stem Cell Ther. 2015;8:16–21. doi: 10.1016/j.hemonc.2014.12.002
   PubMedGoogle Scholar